Lonza’s profits rise on higher sales

摘要

Lonza says its net profts from continuing operations were up approximately 13% in full year 2020, to 732.0 million Swiss francs ($824.6 million) on 7.2% higher sales, to SFr4.51 billion. The strong performance is mainly attributed to the company maintaining business continuity during the COVID-19 pandemic with minimal impacts on operations and supply, as well as to the agreements signed with many customers to manufacture drug substance for COVID-19 vaccine candidates. EBITDA and EBIT increased YOY by 9.0% and 9.2%, to SFr1.38 billion and SFr901 million, respectively. Quarterly fgures have not been disclosed.